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ABSTRACT
The results of blood or marrow transplantation in patients with chemorefractory aggressive lymphoma, that is,
those not responding to conventional-dose chemotherapy at the time of transplant, have been poor. The
relapse rate has been high after autologous bone marrow transplant, whereas allogeneic transplantation has
been associated with excessive transplant-related toxicity. Administration of cyclosporine after autologous
transplantation can induce an autoreactive syndrome that resembles graft-versus-host disease (GVHD). This
syndrome, named autologous graft-versus-host disease, has clear antitumor activity in animal models that can
be enhanced by the addition of cytokines such as -interferon and interleukin-2. A randomized, prospective
study was conducted to evaluate the antitumor effect of autologous graft-versus-host disease induced with
cyclosporine, and augmented by the administration of -interferon and interleukin-2 in patients with che-
morefractory Hodgkin and aggressive non-Hodgkin lymphomas. Fifty-one patients were randomized, 24 to the
autologous GVHD induction arm, and 27 to the noninduction arm after autologous transplant using mobilized
peripheral blood stem cell (PBSC) grafts. There were no differences in treatment-related mortality, overall and
event-free survival (OS, EFS) between both groups; however, in the induction arm, GVHD developed only in
4 patients. The administration of oral cyclosporine followed by interleukin-2 and -interferon is generally not
well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving
autologous PBSC grafts.
© 2007 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
The use of high-dose chemotherapy or chemora-
iotherapy with autologous stem cell rescue is a com-
on strategy to treat patients with relapsed or refrac-
ory lymphoma. However, it is clear that this approach
oes not cure all patients, especially those trans-
lanted with chemorefractory disease, that is, not re-
ponding to conventional-dose chemotherapy at the time of transplant [1-4]. This has triggered an interest
n evaluating the graft-versus-tumor (GVT) effect of
llogeneic bone marrow transplantation (BMT) in
hese diseases in an attempt to exploit the immune
esponse against the neoplastic cells [1,3,5-7]. How-
ver, many patients will lack an HLA matched donor,
nd transplant-related toxicity has been high in che-
oresistant lymphoma patients. Therefore, immuno-herapy utilizing autologous graft-versus-host disease
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J. Bolan˜os-Meade et al.1186GVHD) induction is an attractive approach for these
igh-risk patients.
The administration of cyclosporine after an autol-
gous peripheral blood stem cell (PBSC) or BMT can
nduce an autoimmune clinical syndrome that closely
esembles acute GVHD (aGVHD) in up to 80% of
reated patients [8-11]. This syndrome, autologous
VHD, is a mild, self-limited disease that generally
nvolves only the skin. Histologic changes in the skin
uring autologous GVHD are identical to those of
llogeneic GVHD. In rodent models, autologous
VHD induced by treatment with cyclosporine is
ediated by autoreactive lymphocytes directed
gainst class II histocompatibility (HLA-DR or Ia)
ntigens [12]. These autoreactive lymphocytes also
yse MHC class II positive tumor cells in vivo. Tumor
ell lysis was increased with gamma interferon (-
FN) and interleukin-2 (IL-2) [13,14]. The mecha-
ism of this effect appears to be different for the 2
ytokines: -IFN increases class II expression on the
umor, thereby enhancing tumor cell recognition [13],
hereas IL-2 augments the effector mechanisms [14-
6]. Because most hematopoietic malignancies express
HC class II antigens, autologous GVHD could po-
entially produce a clinical immunologic antitumor
ffect without signiﬁcantly increasing posttransplant
oxicity. Preliminary clinical studies also suggested
hat autologous GVHD might improve disease-free
urvival (DFS) [17,18]. To determine if this approach
rovides an antitumor beneﬁt, a randomized prospec-
ive clinical trial was conducted comparing induction
f autologous GVHD to standard therapy in patients
ith chemotherapy resistant aggressive lymphomas.
ATIENTS, MATERIALS, AND METHODS
tudy Group
All patients receiving autologous transplants for
hemoresistant Hodgkin lymphoma (HL) or aggres-
ive non-Hodgkin lymphoma (NHL) were eligible for
nclusion in this study. Low-grade lymphoma, such as
ollicular grade 1 or 2 or monocytoid B cell lympho-
as were excluded. Chemoresistant disease was de-
ned as: (1) progressive disease developing during or
ithin 6 weeks of completing initial induction ther-
py, or (2) failure to achieve at least an overall partial
esponse (greater than at least a 50% reduction in
umor size assessing the products of the perpendicular
iameters of all measurable lesions) to conventional
alvage therapy following relapse. Patients required an
dequate yield from mobilized peripheral blood har-
est. To ensure patient safety, patients had to have
dequate organ function (renal, cardiac, and pulmo-
ary, and absence of fever) to participate in the trial
osttransplant. preatment
Peripheral blood stem cells were collected after
obilization with cyclophosphamide 2.5 g/m2 and
ranulocyte-colony stimulating factor (G-CSF) (10
g/kg/day). Target yield of apheresis was 5  106
D34 cells/kg with a minimum of 2  106 CD34
ells/kg. After collection, patients were randomized to
he treatment arm or to observation. All patients re-
eived busulfan and cyclophosphamide or cyclophos-
hamide and total body irradiation (TBI) preparative
egimen (if there had been prior radiotherapy total
ody irradiation was not used). Patients assigned to
he GVHD induction arm started cyclosporine (Ne-
ral) at 2 mg/kg twice a day (i.v. formulation was given
o those unable to take pills) starting on the day of the
MT and continued until -IFN and IL-2 were com-
leted. -IFN started when the total white count was
200 cells/mL for 2 consecutive days posttransplant
nd it was given at a dose of 0.025 mg/m2 subcutane-
us every other day for 10 doses. The dose of IL-2
tarted 2 days later and the dose was 1  106 units/m2
ubcutaneous for 18 days. G-CSF was given after the
ransplant until WBC was 1000 for 3 days, 10,000/
m3 on 1 occasion, or 5000/mm3 on 2 occasions.
hould the WBC drop to 1000 on -IFN, G-CSF
as restarted until the white count was consistently
ver 1000.
If clinical Stage I GVHD [19] was diagnosed,
yclosporine, -IFN, and IL-2 were discontinued.
linical GVHD was conﬁrmed by biopsy. GVHD was
reated according to the standard practice at the Johns
opkins Hospital at that time. Cyclosporine levels
ere not followed because previous studies revealed
hat a ﬁxed dose of the drug was capable to induce
utologous GVHD [8-12]. Cyclosporine was adjusted
nly for renal failure according to the following
chedule: creatinine 2.2 mg/dL, decrease dose by
5%; creatinine 3.0, decrease dose by 75%, and
reatinine 4.0; hold drug. The only dose modiﬁca-
ion of -IFN or IL-2 anticipated in this study was
iscontinuation of therapy. This was done if cyclo-
porine was discontinued because of GVHD or unex-
ected toxicity of -IFN and/or IL-2. IL-2 and -IFN
ould be held for 48 hours beyond their anticipated
dministration time point to assess whether a partic-
lar toxicity was related to these drugs.
valuation
Prior to returning home after the transplant, pa-
ients were assessed for response with computed to-
ography scans of chest, abdomen, and pelvis, plus
ther sites of disease. Bone marrow biopsy in patients
ith previous bone marrow involvement and bone
arrow aspirate for tumor marker studies in patients
ho had a known tumor marker pre-BMT were also
reformed.
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Autologous GVHD in Lymphoma 1187tatistical Design
Based on preliminary data, the study was designed
o detect a 40% improvement in 1-year DFS from
0% to 50% in patients randomized to receive autol-
gous GVHD induction. Twenty-ﬁve patients per
rm were required to detect this difference with 80%
ower using a 2-sided 0.05 alpha-level test. Even if the
mprovement were modestly less (ie, 35%), this sam-
le size would detect the difference with relatively
igh power. A 20% improvement in DFS was consid-
red to be clinically important. However, to detect a
0% improvement with the same power would re-
uire 75 patients in each arm. Such a study would
equire a cooperative group study rather than a single-
nstitution trial.
Two analyses of the randomized trial were per-
ormed. The ﬁrst was based on the intention-to-treat
rinciple. It compared the outcome in all patients
andomized to the intervention arm versus all patients
andomized to the other arm. A second analysis of
esults was also performed. The “per-protocol” anal-
sis compared patients randomized to the treatment
rm who actually received the treatment. They were
ompared to those in the control group who met
ligibility criteria to receive IL-2 and -IFN. These
onsisted of screening for renal function, liver func-
ion, pulmonary function, and absence of fever.
The design of the study allowed for early termi-
ation (based on 1 interim analysis halfway through
nrollment) because of evidence of engraftment fail-
re, unexpectedly high transplant-related mortality
TRM), or poor relapse-free survival. To terminate
arly for efﬁcacy (as measured by disease-free sur-
ival), the interim P-value would have had to be
.005.
able 1. Demographics
edian age
emales/males
thnic
iagnosis
DLBC NHL
HL
Anaplastic NHL
Angioimmunoblastic NHL
NK NHL
Burkitt NHL
Hepatosplenic NHL
Follicular Grade 3 NHL
onditioning regimen
one marrow involvement
ailed to achieve a PR to salvage therapy following relapse
rogressive disease less than 6 weeks after completing induction
indicates White; AA, African-American; DLBC, diffuse large
radiation therapy; PR, partial response; Bu-Cy, busulfan and cy
GVHD, graft-versus-host disease.Event-free survival (EFS) was compared between
he 2 arms of the study using a competing risks anal-
sis, where TRM was considered a competing risk.
umulative incidence of relapse at 12 months and
heir 95% conﬁdence intervals were calculated in ad-
ition to a P-value testing the difference in relapse
etween the 2 groups [20]. The “per-protocol” anal-
sis was performed in the same manner. Kaplan-Meier
ethods were used for evaluating time to event (de-
ned as relapse or death) and overall survival (OS).
ncidence of early mortality (60 days from random-
zation) was compared in the 2 arms using a Fisher’s
xact test to compare proportions, and 95% conﬁ-
ence intervals were calculated using an exact bino-
ial procedure. OS was deﬁned as the time from
tudy entry until death by any cause. EFS was deﬁned
s the time from study entry until relapse or death. OS
as deﬁned as the time from study entry until death by
ny cause.
thical Principles
The study was approved by the Johns Hopkins
nstitutional Review Board, and all patients signed
nformed consent. A data safety monitoring commit-
ee supervised the study.
ESULTS
atients
Between 10/14/1997 and 4/16/2002, 54 patients
ere screened and 51 patients were enrolled. Twenty-
our patients were randomized to the treatment arm
nd 27 to the control arm. Table 1 shows the charac-
eristics of the groups.
No GVHD Arm (27) GVHD Arm (24)
41 42
11F/16M 8F/16M
26W/1Asian 21W/3AA
15 12
10 6
0 2
0 2
1 0
1 0
0 1
0 1
17 Bu-Cy/10 Cy-TBI 15 Bu-Cy/9 Cy-TBI
3 4 (1 unknown)
14 12
13 12
HL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; XRT,
sphamide; Cy-TBI, cyclophosphamide and total body irradiation;cell; N
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J. Bolan˜os-Meade et al.1188utologous GVHD
Four patients (16%) in the treatment arm devel-
ped a clinically signiﬁcant rash with biopsy-proven
VHD. The ﬁrst patient developed skin GVHD
stage 2, grade I) while on cyclosporine so did not
eceive -IFN and IL-2. The patient is in a com-
lete remission 6 years after transplant. The second
atient received 5 doses of -IFN and 6 doses of
L-2 and then developed autologous skin GVHD
stage 2, grade I), but succumbed to VOD. The third
atient developed ﬂu-like symptoms and skin GVHD
stage 2, grade I) while on -IFN and IL-2 so the
rugs were discontinued. This patient died of relapsed
ymphoma 6 years after transplant. The fourth patient
eveloped skin GVHD (stage 2, grade I) while on
yclosporine so did not receive -IFN and IL-2. The
atient died of acute respiratory distress syndrome.
o GVHD was observed in the control arm.
urvival and Relapse Analysis
As of April 11, 2006, 34 patients have died, 18 of
7 (66%) in the control arm and 16 of 24 (66%) in the
VHD induction arm. Based on a competing risks
ntent-to-treat analysis, the 12-month incidence of
elapse in the control and treated groups are 63% and
0%, respectively (P .35) (Table 2). The cumulative
ncidence of relapse is shown in Figure 1. TRM was
1% in the treatment group and 7% in the control
roup (P  .23).
In the “per-protocol” analysis, there are 18 pa-
ients in the treated group who completed treatment
nd they were compared to 25 patients in the control
roup who would have been eligible to begin the
xperimental treatment. The per-protocol analysis
howed no difference in the incidence of relapse as
hown in Figure 2, with GVHD induction and control
roups having 12-month incidence of relapse of 61%
nd 60%, respectively (P .84) as described in Table 2.
here were no differences in EFS (death or relapse) or
S between both groups by either analysis (“per pro-
ocol” or intent to treat) (Figure 3).
dverse Events
Of the 24 patients who started cyclosporine, 6 did
ot begin IL-2 or -IFN: 1 because of renal failure, 1
able 2. 12-Month Cumulative Incidence of Relapse
Estimate
95% Confidence
Interval P-value*
ntention to treat
Control group 0.63 (0.44-0.82) .35
Treated group 0.50 (0.29-0.71)
Per-protocol” analysis
Control group 0.60 (0.40-0.80) .84
Treated group 0.61 (0.37-0.85)P-value testing the difference in survival curves. 2ecause of renal failure and skin GVHD, 1 because of
apillary leak syndrome, 1 because of skin GVHD, 1
ecause of VOD of the liver, and 1 because of VOD
enal failure. Eight patients stopped IL-2 and/or
-IFN early: because of eosinophilia (15,390/mm3,
 1), ﬂu-like symptoms (n  2), fever (n  1),
apillary leak syndrome and renal failure (n  1),
OD and skin GVHD (n  1), mental status changes
n  1), and ﬂu-like symptoms and skin GVHD (n 
). Ten patients tolerated the entire induction therapy
ie, cyclosporine, -IFN, and IL-2). Seven deaths oc-
urred prior to day 60: 5 among patients randomized
o autologous GVHD and 2 in the control group (P
igure 1. Competing risks analysis of relapse and death, based on
ntention to treat analysis (n 24 patients randomized to the treat-
ent group, n 27 patients randomized to control group).
igure 2. Competing risks analysis of relapse and death, based on
per protocol” analysis (n 18 patients in the treatment group, n
5 patients in the control group).
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Autologous GVHD in Lymphoma 118923); however, only 1 of these patients received -IFN
nd IL-2. Four of the 7 deaths were related to known
reparative-regimen related toxicities (adult respira-
ory distress syndrome, interstitial pneumonitis,
OD/liver failure), whereas 3 patients died of pro-
ressive lymphoma.
ISCUSSION
The group of patients with refractory disease in-
luded in the present trial historically has a very poor
utcome. Philip et al. [21] studied 100 such patients
ith intermediate-grade or high-grade NHL. Thirty-
our percent had disease that had been refractory to
rimary chemotherapy, and 66% had had a complete
emission with primary chemotherapy but later re-
apsed. After high-dose therapy and bone marrow
ransplantation, the actuarial 3-year DFS was zero in
he refractory group, 14% in the resistant-relapse
roup, and 36% in the sensitive-relapse group. Even
hen posttransplant therapy may improve the out-
ome of these patients [4], the results are far from
atisfactory. Our experience is similar with poor re-
ults in this group of patients. Aksentijevich et al. [3]
eported that patients with resistant diffuse large cell
HL at the time of BMT, only 12.5% and 19.1% of
atients survived 3 years following allo- or auto-stem
ell transplantation (SCT), respectively (P  .08). Ak-
ek et al. [1] analyzed the outcome of 157 consecutive
atients with relapsed or refractory HL, who under-
ent SCT between March 1985 and April 1998. Dis-
ase status before SCT (sensitive relapse if responding
o conventional-dose therapy or resistant disease if
ot) was an independent predictor of EFS and relapse
Figure 3. A, Overall survival (intention to treat analysis), andP  .0001). GGVHD is associated with a GVT as evidenced by
decreased relapse rate after allogeneic SCT [22]. In
nimal models and exploratory clinical trials, autolo-
ous GVHD also appears to induce a GVT effect
10,11]. Autologous GVHD has been observed using
any “induction” regimens. Ratanatharathorn et al.
23] reported on the use of cyclosporine and -IFN in
small clinical trial [23]. The study showed that this
pproach was feasible, with a majority of patients
eveloping autologous GVHD after BMT. Cyclo-
porine-induced autologous GVHD has been studied
ntensively by our group [8,10-12,14,24-27]. From the
arly clinical studies, it was clear that the administra-
ion of cyclosporine could predictably induce skin
VHD after BMT [8,10,11]. Jones et al. reported that
of 5 patients with lymphoma developed autologous
VHD after exposure to cyclosporine. Later on, pa-
ients with leukemia that received a nonpurged [11] or
urged [10] SCT exposed to cyclosporine also devel-
ped autologous GVHD in high proportions (close to
0%). Vogelsang et al. [18] reported a clinical trial on
atients with hematologic malignancies receiving cy-
losporine and IFN to induce autologous GVHD in
atients receiving 4HC-purged marrow grafts. Treat-
ent with cyclosporine and -IFN after BMT was
ell tolerated and did not impair engraftment. EFS
ith a median of 964 days of follow-up was 44%.
linically signiﬁcant GVHD was seen in 20% of
ases.
In the current study, only 4 patients developed
linically apparent GVHD. This is in marked contrast
o our previous autologous GVHD trials where the
ajority of patients developed clinical evidence of
VHD [5,8,18]. In animal studies of autologous
t-free (relapse or death) survival (intention to treat analysis).VHD, immunologic effector cells and antitumor
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J. Bolan˜os-Meade et al.1190ctivity was seen only in those animals actually devel-
ping the syndrome [12,14]. Thus, the lack of clini-
ally signiﬁcant antitumor effect in the current trial
ay have resulted from the inability to induce the
yndrome in most patients. The relatively low rate of
bserved autologous GVHD in the present study may
esult from the use of mobilized peripheral blood
nstead of BM. Previous studies have also found a
uch lower incidence of autologous GVHD utilizing
obilized peripheral blood grafts rather than BM
17,26]; this primarily appears to be the result of the
nfusion of a large number of T cells and monocytes
hat may downregulate the development of autologous
VHD [17,26,28,29]. Mobilized peripheral blood
ontains approximately 10 times more T cells than do
one marrow grafts [30]. Interestingly, animal studies
uggest that the transfer of mature T cells along with
he graft can modify the ability to induce autologous
VHD [31-33]. Indeed, it has been reported that
utologous GVHD will not occur unless T cells are
emoved from the peripheral blood graft [17,34]. The
se of oral cyclosporine (instead of parenteral) may
lso play an important role, as changes in bioavailabil-
ty of the drug in the thymus may prevent the induc-
ion of autoreactive T cells [35]. Other factors such as
he criteria for diagnosis of GVHD and the use of
iopsies in patients without symptoms can also affect
he expected frequency of GVHD [11,18,36,36-39].
n the current study, patients had biopsies only when
hey developed clinical evidence of GVHD and strict
riteria (standard at our institution) for the diagnosis
f skin GVHD were followed (lymphocytic inﬁltrate
ith dyskeratosis). Certainly, it is possible that a GVT
as present but not detected because of the sample
ize (see the Statistical Design section) or because of a
better than expected” outcome in the control arm
21]. This study was designed to detect a 40% im-
rovement in 1-year DFS from 10% to 50% in pa-
ients randomized to receive autologous GVHD in-
uction. The idea behind this ambitious goal was that
f a large difference was obtained, we would be conﬁ-
ent that the effect found was substantial, which
ould justify expanding rapidly into other patient
roups. Conversely, if the effect was less clear (as it
appened), a much larger patient population would be
eeded to detect any beneﬁt. Further studies would
equire cooperative group trials as the 1 currently
onducted by the Children’s Oncology Group that
opefully will help to clarify this issue.
EFERENCES
1. Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results
of blood and marrow transplantation for Hodgkin’s lymphoma.
J Clin Oncol. 2001;19:4314-4321.2. Kasamon YL, Jones RJ, Diehl LF, et al. Outcomes of autolo-
gous and allogeneic blood or marrow transplantation for mantle
cell lymphoma. Biol Blood Marrow Transplant. 2005;11:39-46.
3. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E,
Flinn IW. Autologous versus allogeneic blood and marrow
transplantation for relapsed diffuse large cell non-Hodgkin’s
lymphoma. Biol Blood Marrow Transplant. 2006;12:965-972.
4. Rapoport AP, Guo C, Badros A. et al. Autologous stem cell
transplantation followed by consolidation chemotherapy for
relapsed or refractory Hodgkin’s lymphoma. Bone Marrow
Transplant. 2004;34:883-890.
5. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of
a graft-versus-lymphoma effect associated with allogeneic bone
marrow transplantation. Blood. 1991;77:649-653.
6. van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic
bone marrow transplantation for low-grade lymphoma. Blood.
1998;92:1832-1836.
7. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT
registry matched study of allogeneic stem cell transplants for
lymphoma: allogeneic transplantation is associated with a lower
relapse rate but a higher procedure-related mortality rate than
autologous transplantation. Bone Marrow Transplant. 2003;31:
667-678.
8. Jones RJ, Vogelsang GB, Hess AD, et al. Induction of graft-
versus-host disease after autologous bone marrow transplanta-
tion. Lancet. 1989;333:754-757.
9. Vogelsang GB, Jones RJ, Hess AD, Geller R, Schucter L,
Santos GW. Induction of autologous graft-versus-host disease.
Transplant Proc. 1989;21(1 Pt 3):2997-2998.
0. Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Hess AD,
Santos GW. Cyclosporine-induced graft-versus-host disease af-
ter autologous bone marrow transplantation for acute myeloid
leukemia. Leuk Lymphoma. 1993;11:215-220.
1. Yeager AM, Vogelsang GB, Jones RJ, et al. Induction of cuta-
neous graft-versus-host disease by administration of cyclospor-
ine to patients undergoing autologous bone marrow transplan-
tation for acute myeloid leukemia. Blood. 1992;79:3031-3035.
2. Hess AD, Horwitz L, Beschorner WE, Santos GW. Develop-
ment of graft-vs.-host disease-like syndrome in cyclosporine-
treated rats after syngeneic bone marrow transplantation. I.
Development of cytotoxic T lymphocytes with apparent poly-
clonal anti-Ia speciﬁcity, including autoreactivity. J Exp Med.
1985;161:718-730.
3. Noga SJ, Horwitz L, Kim H, Laulis MK, Hess AD. Interferon-
gamma potentiates the antitumor effect of cyclosporine-in-
duced autoimmunity. J Hematother. 1992;1:75-84.
4. Geller RB, Esa AH, Beschorner WE, Frondoza CG, Santos
GW, Hess AD. Successful in vitro graft-versus-tumor effect
against an Ia-bearing tumor using cyclosporine-induced synge-
neic graft-versus-host disease in the rat. Blood. 1989;74:1165-
1171.
5. Soiffer RJ, Murray C, Cochran K, et al. Clinical and immuno-
logic effects of prolonged infusion of low-dose recombinant
interleukin-2 after autologous and T-cell-depleted allogeneic
bone marrow transplantation. Blood. 1992;79:517-526.
6. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose
interleukin-2 on disease relapse after T-cell-depleted allogeneic
bone marrow transplantation. Blood. 1994;84:964-971.
7. Miura Y, Ueda M, Zeng W. et al. Induction of autologous
graft-versus-host disease with cyclosporin A after peripheral
blood stem cell transplantation: analysis of factors affecting
induction. J Allergy Clin Immunol. 2000;106:S51-S57.
11
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
Autologous GVHD in Lymphoma 11918. Vogelsang G, Bitton R, Piantadosi S, et al. Immune modulation in
autologous bone marrow transplantation: cyclosporine and gam-
ma-interferon trial. Bone Marrow Transplant. 1999;24:637-640.
9. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus
conference on acute GVHD grading. Bone Marrow Transplant.
1995;15:825-828.
0. Gray RJ. A class of k-sample tests for comparing the cumulative
incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
1. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and
autologous bone marrow transplantation after failure of con-
ventional chemotherapy in adults with intermediate-grade or
high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1987;
316:1493-1498.
2. Bolaños-Meade J, Vogelsang GB. Acute graft-versus-host dis-
ease. Clin Adv Hematol Oncol. 2004;2:672-682.
3. Ratanatharathorn V, Uberti J, Karanes C, et al. Phase I study of
alpha-interferon augmentation of cyclosporine-induced graft
versus host disease in recipients of autologous bone marrow
transplantation. Bone Marrow Transplant. 1994;13:625-630.
4. Wu JM, Bensen-Kennedy D, Miura Y, et al. The effects of
interleukin 10 and interferon gamma cytokine gene polymor-
phisms on survival after autologous bone marrow transplanta-
tion for patients with breast cancer. Biol Blood Marrow Trans-
plant. 2005;11:455-464.
5. Miura Y, Thoburn CJ, Bright EC, et al. Characterization of the
T-cell repertoire in autologous graft-versus-host disease
(GVHD): evidence for the involvement of antigen-driven T-
cell response in the development of autologous GVHD. Blood.
2001;98:868-876.
6. Miura Y, Ueda M, Takami A, Shiobara S, Nakao S, Hess AD.
Enhancement of cyclosporin A-induced autologous graft-ver-
sus-host disease after peripheral blood stem cell transplantation
by utilizing selected CD34() cells. Bone Marrow Transplant.
2003;32:785-790.
7. Miura Y, Thoburn CJ, Bright EC, Chen W, Nakao S, Hess
AD. Cytokine and chemokine proﬁles in autologous graft-
versus-host disease (GVHD): interleukin 10 and interferon
gamma may be critical mediators for the development of au-
tologous GVHD. Blood. 2002;100:2650-2658.
8. Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E,
et al. Peripheral blood mobilization of different lymphocyte and
dendritic cell subsets with the use of intermediate doses of
G-CSF in patients with non-Hodgkin’s lymphoma and multi-
ple myeloma. Ann Hematol. 2006;85:308-314.9. Condomines M, Quittet P, Lu ZY, et al. Functional regulatory
T cells are collected in stem cell autografts by mobilization
with high-dose cyclophosphamide and granulocyte colony-
stimulating factor. J Immunol. 2006;176:6631-6639.
0. Kusnierz-Glaz CR, Still BJ, Amano M, et al. Granulocyte
colony-stimulating factor-induced comobilization of CD4	
CD8	 T cells and hematopoietic progenitor cells (CD34) in
the blood of normal donors. Blood. 1997;89:2586-2595.
1. Fischer AC, Hess AD. Age-related factors in cyclosporine-
induced syngeneic graft-versus-host disease: regulatory role of
marrow-derived T lymphocytes. J Exp Med. 1990;172:85-94.
2. Fischer AC, Laulis MK, Horwitz L, Beschorner WE, Hess A.
Host resistance to cyclosporine induced syngeneic graft-versus-
host disease. Requirement for two distinct lymphocyte subsets.
J Immunol. 1989;143:827-832.
3. Wu DY, Goldschneider I. Cyclosporin A-induced autologous
graft-versus-host disease: a prototypical model of autoimmu-
nity and active (dominant) tolerance coordinately induced by
recent thymic emigrants. J Immunol. 1999;162:6926-6933.
4. Sica S, Chiusolo P, Salutari P, et al. Autologous graft-versus-
host disease after CD34-puriﬁed autologous peripheral blood
progenitor cell transplantation. J Hematother Stem Cell Res.
2000;9:375-379.
5. Jenkins MK, Schwartz RH, Pardoll DM. Effects of cyclospor-
ine A on T cell development and clonal deletion. Science. 1988;
241:1655-1658.
6. van der Wall E, Horn T, Bright E, et al. Autologous graft-
versus-host disease induction in advanced breast cancer: role of
peripheral blood progenitor cells. Br J Cancer. 2000;83:1405-
1411.
7. Giralt S, Weber D, Colome M, et al. Phase I trial of cyclosporine-
induced autologous graft-versus-host disease in patients with mul-
tiple myeloma undergoing high-dose chemotherapy with autolo-
gous stem-cell rescue. J Clin Oncol. 1997;15:667-673.
8. Streetly M, Kazmi M, Radia D, Hoyle C, Schey SA. Second
autologous transplant with cyclosporin/interferon alpha-in-
duced graft versus host disease for patients who have failed
ﬁrst-line consolidation. Bone Marrow Transplant. 2004;33:1131-
1135.
9. Marín GH, Menna ME, Bergna MI, et al. Induction of anti-
tumor activity following autologous stem cell transplantation:
immunotherapeutic implications. Transplant Proc. 2001;33:
2004-2007.
